Table 2.

States with expanded financial support in the past year for medication-assisted opioid treatment through Medicaid or the state alcohol and drug agency, by medication, based on National Association of State Alcohol and Drug Abuse Directors questionnaire, 2014-2015^a

State	Methadone	Buprenorphine	Extended- Release Injectable Naltrexone
Alabama	✓ M, S
California		✓ M
Colorado	✓ M	✓ M	✓ M, S
Delaware	✓ S	✓ S	✓ S
District of Columbia	✓ M, S	✓ M
Florida			✓ S
Georgia	✓ S
Illinois	✓ S		✓ S
Indiana	✓ S
Kentucky		✓ M	✓ M
Louisiana	✓ M, S
Maryland	✓ M, S	✓ M, S	✓ M, S
Michigan			✓ S
Missouri			✓ S
New Hampshire	✓ M	✓ M, S	✓ M
New Jersey	✓ M	✓ M	✓ S
New Mexico	✓ M	✓ M	✓ S
New York		✓ M	✓ S
North Carolina	✓ M	✓ M
Ohio	✓ M	✓ M	✓ M
Oklahoma	✓ S	✓ S	✓ S
Pennsylvania		✓ M, S	✓ M, S
Tennessee			✓ S
Texas	✓ M	✓ M	✓ M
Vermont	✓ M, S	✓ M, S	✓ M
Virginia	✓ M	✓ M
Washington	✓ M	✓ M
West Virginia		✓ M	✓ M
Wisconsin	✓ M	✓ M	✓ M

Abbreviations: M, Medicaid; S, state alcohol and drug agency.

^aData were based on responses to the following questions: (1) In the past year, has your state expanded financial support for the use of methadone in the treatment of opioid or heroin dependence, either through the state alcohol and drug agency or Medicaid? (2) In the past year, has your state expanded financial support for the use of buprenorphine in the treatment of opioid or heroin dependence, either through the state alcohol and drug agency or Medicaid? and (3) In the past year, has your state expanded financial support for the use of extended-release injectable naltrexone in the treatment of opioid or heroin dependence, either through the state alcohol and drug agency or Medicaid? Based on 51 responses from all 50 states and Washington, DC, to a questionnaire about initiatives to address the opioid crisis. Blank cells indicate no, unsure, or nonresponse.